David C. Francisco's most recent trade in Organogenesis Holdings Inc - Ordinary Shares - Class A was a trade of 170,841 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 170,841 | 170,841 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 165,156 | 559,095 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 19,528 | 397,703 (0%) | 0% | 3.7 | 72,254 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 11,765 | 417,231 (0%) | 0% | 3.7 | 43,531 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 2,960 | 394,743 (0%) | 0% | 3.7 | 10,952 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 804 | 393,939 (0%) | 0% | 3.7 | 2,975 | Class A Common Stock |
| Organogenesis Holdings Inc... | Francisco David C. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 289,915 | 289,915 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | C. Francisco David | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 160,350 | 428,996 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | Francisco David C. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.68 per share. | 15 Feb 2024 | 18,966 | 272,963 (0%) | 0% | 3.7 | 69,795 | Class A Common Stock |
| Organogenesis Holdings Inc... | Francisco C. David | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.68 per share. | 15 Feb 2024 | 3,513 | 269,450 (0%) | 0% | 3.7 | 12,928 | Class A Common Stock |
| Organogenesis Holdings Inc... | C. David Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.48 per share. | 15 Feb 2024 | 804 | 268,646 (0%) | 0% | 3.5 | 2,798 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 287,892 | 287,892 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 242,508 | 291,929 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.92 per share. | 15 Feb 2023 | 3,506 | 50,374 (0%) | 0% | 2.9 | 10,238 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. | 15 Feb 2023 | 953 | 49,421 (0%) | 0% | 2.8 | 2,621 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 95,692 | 95,692 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 40,348 | 56,709 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.03 per share. | 15 Feb 2022 | 1,876 | 54,833 (0%) | 0% | 8.0 | 15,064 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 15 Feb 2022 | 953 | 53,880 (0%) | 0% | 7.8 | 7,414 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 83,955 | 83,955 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 10,965 | 16,361 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 43,239 | 43,239 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 5,396 | 5,396 (0%) | 0% | 0 | Class A Common Stock |